Jacobus Burggraaf
Centre for Human Drug Research, Leiden University Medical Center
Papers
4
Total Citations
194
H-Index
4
About
Jacobus Burggraaf is a pioneering clinical pharmacologist and surgeon-scientist whose work centers on intraoperative fluorescence imaging to improve surgical precision and patient outcomes. His research focuses on developing and validating near-infrared (NIR) fluorescence-guided surgery, particularly using indocyanine green (ICG), to address critical challenges in colorectal and urologic oncology. Burggraaf led the landmark AVOID trial (84 citations), a multicentre, randomised, phase 3 study demonstrating that ICG fluorescence bowel perfusion assessment significantly reduces anastomotic leakage in minimally invasive colorectal surgery—a practice-changing contribution. He also spearheaded the first-in-patient study of OTL78 (54 citations), a novel tracer for real-time fluorescence imaging of prostate-specific membrane antigen (PSMA)-positive prostate cancer, showing feasibility in a phase 2a trial. His work on ICG-guided margin assessment during colorectal liver metastasis resection (49 citations) addresses the critical problem of unintended tumor-positive margins. Additionally, Burggraaf has systematically reviewed dyes for ureter identification during laparoscopic surgery, aiming to prevent iatrogenic injury. With over 190 citations across these key studies, his translational research is directly shaping safer, more effective surgical practices.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4